Skip to main content
Erschienen in: Die Radiologie 4/2011

01.04.2011 | Leitthema

Klinische und bildgebende Diagnostik bei Morbus Parkinson und Multisystematrophie

verfasst von: Dr. K. I. Schmidt, J. Spiegel, W. Reith

Erschienen in: Die Radiologie | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Diagnose des Morbus Parkinson (Parkinson’s disease, PD) und der Multisystematrophie (MSA) erfolgt primär klinisch, stellt jedoch mitunter auch einen erfahrenen Neurologen vor eine große Herausforderung. Die neuroradiologische Bildgebung kann bei der Diagnosefindung helfen, dient jedoch in erster Linie dazu, andere Erkrankungen wie Normaldruckhydrozephalus, Multiinfarktdemenz und zerebelläre Läsionen auszuschließen. Nuklearmedizinische Methoden können zusätzlich zur Diagnose und Differenzialdiagnose bei PD und MSA herangezogen werden.
Literatur
1.
Zurück zum Zitat Antonini A, Benti R, De Notaris R et al (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24:149–150PubMedCrossRef Antonini A, Benti R, De Notaris R et al (2003) 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 24:149–150PubMedCrossRef
2.
Zurück zum Zitat Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503-510PubMedCrossRef Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503-510PubMedCrossRef
3.
Zurück zum Zitat Benamer HT, Oertel WH, Patterson J et al (2003) Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 18:977–984PubMedCrossRef Benamer HT, Oertel WH, Patterson J et al (2003) Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 18:977–984PubMedCrossRef
4.
Zurück zum Zitat Bernheimer H, Birkmayer W, Hornykiewicz O et al (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20:415–455PubMedCrossRef Bernheimer H, Birkmayer W, Hornykiewicz O et al (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20:415–455PubMedCrossRef
5.
Zurück zum Zitat Booij J, Busemann Sokole E et al (1998) Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med Mol Imaging 25:24–30CrossRef Booij J, Busemann Sokole E et al (1998) Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med Mol Imaging 25:24–30CrossRef
6.
Zurück zum Zitat Braak H, Ghebremedhin E, Rüb U et al (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134PubMedCrossRef Braak H, Ghebremedhin E, Rüb U et al (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134PubMedCrossRef
7.
Zurück zum Zitat Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 11:351–355PubMedCrossRef Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 11:351–355PubMedCrossRef
8.
Zurück zum Zitat Deuschl G, Krack P (1999) Morbus Parkinson. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik, Bd 2. Thieme, Stuttgart New York, S 49–69 Deuschl G, Krack P (1999) Morbus Parkinson. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik, Bd 2. Thieme, Stuttgart New York, S 49–69
9.
Zurück zum Zitat Druschky A, Hilz MJ, Platsch G et al (2000) Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3–12PubMedCrossRef Druschky A, Hilz MJ, Platsch G et al (2000) Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3–12PubMedCrossRef
10.
Zurück zum Zitat Eerola J, Tienari PJ, Kaakkola S et al (2005) How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 76:1211–1216PubMedCrossRef Eerola J, Tienari PJ, Kaakkola S et al (2005) How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 76:1211–1216PubMedCrossRef
11.
Zurück zum Zitat Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426PubMedCrossRef Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426PubMedCrossRef
12.
Zurück zum Zitat Hughes A, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson‘s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef Hughes A, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson‘s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef
13.
Zurück zum Zitat Hughes A, Ben-Shlomo Y, Daniel SE et al (1993) What feasures improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 43:1629–1630 Hughes A, Ben-Shlomo Y, Daniel SE et al (1993) What feasures improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 43:1629–1630
14.
Zurück zum Zitat Ichise M, Kim YJ, Ballinger JR et al (1999) SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206–1214PubMed Ichise M, Kim YJ, Ballinger JR et al (1999) SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206–1214PubMed
15.
Zurück zum Zitat Innis RB, Marek KL, Sheff K et al (1999) Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14:436–442PubMedCrossRef Innis RB, Marek KL, Sheff K et al (1999) Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14:436–442PubMedCrossRef
16.
Zurück zum Zitat Khafagi FA, Shapiro B, Fischer M et al (1991) Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 18:191–198CrossRef Khafagi FA, Shapiro B, Fischer M et al (1991) Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 18:191–198CrossRef
17.
Zurück zum Zitat Kim GM, Kim SE, Lee WY (2000) Preclinical impairment of the striatal dopamine transporter system in sporadic olivopontocerebellar atrophy: studied with [123I] ß-CIT and SPECT. Eur Neurol 43:23–29PubMedCrossRef Kim GM, Kim SE, Lee WY (2000) Preclinical impairment of the striatal dopamine transporter system in sporadic olivopontocerebellar atrophy: studied with [123I] ß-CIT and SPECT. Eur Neurol 43:23–29PubMedCrossRef
18.
Zurück zum Zitat Kim YJ, Ichise M, Ballinger JR et al (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303–312PubMedCrossRef Kim YJ, Ichise M, Ballinger JR et al (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303–312PubMedCrossRef
19.
Zurück zum Zitat Köllensperger M, Seppi K, Liener C et al (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771–1776PubMedCrossRef Köllensperger M, Seppi K, Liener C et al (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771–1776PubMedCrossRef
20.
Zurück zum Zitat Lee PH, Yeo SH, Kim HJ, Youm HY (2006) Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease and multiple system atrophy. Mov Disord 21:1975–1977PubMedCrossRef Lee PH, Yeo SH, Kim HJ, Youm HY (2006) Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease and multiple system atrophy. Mov Disord 21:1975–1977PubMedCrossRef
21.
Zurück zum Zitat Leung A, Shapiro B, Hattner R et al (1997) Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38:1352–1357PubMed Leung A, Shapiro B, Hattner R et al (1997) Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38:1352–1357PubMed
22.
Zurück zum Zitat Litvan I, Goetz CG, Jankovic J et al (1997) What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54:937–944PubMed Litvan I, Goetz CG, Jankovic J et al (1997) What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54:937–944PubMed
23.
Zurück zum Zitat Lumbroso J, Hartmann O, Schlumberger M (1991) Therapeutic use of [131I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. „Société Francaise d’Oncologie Pediatrique“ and Nuclear Medicine Co-investigators. J Nucl Biol Med 35:220–223PubMed Lumbroso J, Hartmann O, Schlumberger M (1991) Therapeutic use of [131I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. „Société Francaise d’Oncologie Pediatrique“ and Nuclear Medicine Co-investigators. J Nucl Biol Med 35:220–223PubMed
24.
Zurück zum Zitat Mairs R (1999) Neuroblastoma therapy using radiolabelled [131I] meta-iodobenzylguanidine ([131I] MIBG) in combination with other agents. Eur J Cancer 35:1171–1173PubMedCrossRef Mairs R (1999) Neuroblastoma therapy using radiolabelled [131I] meta-iodobenzylguanidine ([131I] MIBG) in combination with other agents. Eur J Cancer 35:1171–1173PubMedCrossRef
25.
Zurück zum Zitat Nagamachi S, Wakamatsu H, Kiyohara S et al (2008) Usefulness of rCBF analysis in diagnosing Parkinson’s disease: supplemental role with myocardial MIBG scintigraphy. Ann Nucl Med 22:557–564PubMedCrossRef Nagamachi S, Wakamatsu H, Kiyohara S et al (2008) Usefulness of rCBF analysis in diagnosing Parkinson’s disease: supplemental role with myocardial MIBG scintigraphy. Ann Nucl Med 22:557–564PubMedCrossRef
26.
Zurück zum Zitat Nagayama H, Hamamoto M, Ueda M et al (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251PubMedCrossRef Nagayama H, Hamamoto M, Ueda M et al (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251PubMedCrossRef
27.
Zurück zum Zitat Nakajo M, Shapiro B, Copp J et al (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 24:672–682PubMed Nakajo M, Shapiro B, Copp J et al (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 24:672–682PubMed
28.
Zurück zum Zitat Okada Y, Ito Y, Aida J et al (2004) Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 54:682–687PubMedCrossRef Okada Y, Ito Y, Aida J et al (2004) Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 54:682–687PubMedCrossRef
29.
Zurück zum Zitat Orimo S, Ozawa E, Nakade S et al (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194PubMedCrossRef Orimo S, Ozawa E, Nakade S et al (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194PubMedCrossRef
30.
Zurück zum Zitat Orimo S, Takahashi A, Uchihara T et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17:24–30PubMedCrossRef Orimo S, Takahashi A, Uchihara T et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17:24–30PubMedCrossRef
31.
Zurück zum Zitat Orimo S (2008) Clinical and pathological study on early diagnosis of Parkinson’s disease and dementia with Lewy bodies. Rinsho Shinkeigaku 48:11–24PubMed Orimo S (2008) Clinical and pathological study on early diagnosis of Parkinson’s disease and dementia with Lewy bodies. Rinsho Shinkeigaku 48:11–24PubMed
32.
Zurück zum Zitat Osborn AG, Salzman KL, Barkovich AJ (2010) Diagnostic imaging. Brain 10:78–85 Osborn AG, Salzman KL, Barkovich AJ (2010) Diagnostic imaging. Brain 10:78–85
33.
Zurück zum Zitat Parkinson J (1817) An essay on the shaking palsy. London Parkinson J (1817) An essay on the shaking palsy. London
34.
Zurück zum Zitat Pirker W, Asenbaum S, Bencsits G et al (2000) [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158–1167PubMedCrossRef Pirker W, Asenbaum S, Bencsits G et al (2000) [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158–1167PubMedCrossRef
35.
Zurück zum Zitat Plotkin M, Amthauer H, Klaffke S et al (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112:677–692PubMedCrossRef Plotkin M, Amthauer H, Klaffke S et al (2005) Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 112:677–692PubMedCrossRef
36.
Zurück zum Zitat Poewe W, Wenning GK, Gerlach M et al (1999) Nicht-idiopathische Parkinson-Syndrome. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik, Bd 2. Thieme, Stuttgart New York, S 69–78 Poewe W, Wenning GK, Gerlach M et al (1999) Nicht-idiopathische Parkinson-Syndrome. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik, Bd 2. Thieme, Stuttgart New York, S 69–78
37.
Zurück zum Zitat Reichmann H (2008) Neurodegenerative Erkrankungen. UNI-MED, Bremen Reichmann H (2008) Neurodegenerative Erkrankungen. UNI-MED, Bremen
38.
Zurück zum Zitat Sawada H, Oeda T, Yamamoto K et al (2009) Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson’s disease. Eur J Neurol 16:174–182PubMedCrossRef Sawada H, Oeda T, Yamamoto K et al (2009) Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson’s disease. Eur J Neurol 16:174–182PubMedCrossRef
39.
Zurück zum Zitat Seibyl JP, Marek K, Sheff K et al (1998) Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 39:1500–1508PubMed Seibyl JP, Marek K, Sheff K et al (1998) Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 39:1500–1508PubMed
40.
Zurück zum Zitat Shapiro B, Copp JE, Sisson JC et al (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585PubMed Shapiro B, Copp JE, Sisson JC et al (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585PubMed
41.
Zurück zum Zitat Sisson J, Shulkin B (1999) Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 43:217–223PubMed Sisson J, Shulkin B (1999) Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 43:217–223PubMed
42.
Zurück zum Zitat Spiegel J, Hellwig D, Möllers MO et al (2006) Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain 129:1188–1193PubMedCrossRef Spiegel J, Hellwig D, Möllers MO et al (2006) Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain 129:1188–1193PubMedCrossRef
43.
Zurück zum Zitat Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335PubMedCrossRef Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335PubMedCrossRef
44.
Zurück zum Zitat Spiegel J, Hellwig D, Farmakis G et al (2007) Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov Disord 22:1004–1008PubMedCrossRef Spiegel J, Hellwig D, Farmakis G et al (2007) Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov Disord 22:1004–1008PubMedCrossRef
45.
Zurück zum Zitat Taki J, Nakajima K, Hwang EH et al (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med Mol Imaging 27:566–573CrossRef Taki J, Nakajima K, Hwang EH et al (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med Mol Imaging 27:566–573CrossRef
46.
Zurück zum Zitat Turner B (1968) Pathology of paralysis agitans. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. Vol 6: Parkinson’s disease. North-Holland Publishing Company, Amsterdam; Wiley & Sons, New York, pp 212–217 Turner B (1968) Pathology of paralysis agitans. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. Vol 6: Parkinson’s disease. North-Holland Publishing Company, Amsterdam; Wiley & Sons, New York, pp 212–217
47.
Zurück zum Zitat Van Laere K, Ceuninck L de, Dom R et al (2004) Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 31:1119–1127 Van Laere K, Ceuninck L de, Dom R et al (2004) Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 31:1119–1127
48.
Zurück zum Zitat Varrone A, Marek KL, Jennings D et al (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1023–1032PubMedCrossRef Varrone A, Marek KL, Jennings D et al (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1023–1032PubMedCrossRef
49.
Zurück zum Zitat Wieland DM, Wu J, Brown LE et al (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I] iodobenzylguanidine. J Nucl Med 21:349–353PubMed Wieland DM, Wu J, Brown LE et al (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I] iodobenzylguanidine. J Nucl Med 21:349–353PubMed
50.
Zurück zum Zitat Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67PubMedCrossRef Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67PubMedCrossRef
Metadaten
Titel
Klinische und bildgebende Diagnostik bei Morbus Parkinson und Multisystematrophie
verfasst von
Dr. K. I. Schmidt
J. Spiegel
W. Reith
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Die Radiologie / Ausgabe 4/2011
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-010-2095-5

Weitere Artikel der Ausgabe 4/2011

Die Radiologie 4/2011 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.